Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium - Episode 6

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

January 9, 2023

Hans Hammers, MD, PhD, Moshe Ornstein, MD

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

Now Viewing

EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC

EP. 8: Emerging Data in Non-Clear Cell RCC Treatment

EP. 9: Exciting Investigational Therapies in Advanced RCC